Metabolic activation of intrahepatic CD8+ T cells and NKT cells causes nonalcoholic steatohepatitis and liver cancer via cross-talk with hepatocytes

Cancer Cell

Volumn 26, Issue 4, 2014, Pages 549-564

  Wolf, MonikaJulia ^a   Adili, Arlind ^b   Piotrowitz, Kira ^c   Abdullah, Zeinab ^c   Boege, Yannick ^a   Stemmer, Kerstin ^b   Ringelhan, Marc ^b,d   Simonavicius, Nicole ^b   Egger, Michèle ^a   Wohlleber, Dirk ^b   Lorentzen, Anna ^b   Einer, Claudia ^e   Schulz, Sabine ^e   Clavel, Thomas ^b   Protzer, Ulrike ^b   Thiele, Christoph ^c   Zischka, Hans ^e   Moch, Holger ^a   Tschöp, Matthias ^b   Tumanov, AlexeiV ^f   Haller, Dirk ^b   Unger, Kristian ^e   Karin, Michael ^g   Kopf, Manfred ^h   Knolle, Percy ^b,c   Weber, Achim ^a   Heikenwalder, Mathias ^b   more..

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF BONN   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f TRUDEAU INSTITUTE   (United States)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h ETH ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER INCIDENCE; CD8+ T LYMPHOCYTE; CELL ACTIVATION; CELL DIFFERENTIATION; CELL INFILTRATION; CELL INTERACTION; CHOLESTEROL BLOOD LEVEL; COMPARATIVE GENOMIC HYBRIDIZATION; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; GENE EXPRESSION; IMMUNOBLOTTING; LIVER CARCINOGENESIS; LIVER CELL; LIVER CELL CARCINOMA; MALE; METABOLIC ACTIVATION; MOUSE; MOUSE MODEL; NATURAL KILLER T CELL; NONALCOHOLIC FATTY LIVER; NONHUMAN; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T CELL DEPLETION; WEIGHT GAIN; WHOLE BODY MRI; ANIMAL; C57BL MOUSE; FATTY LIVER; HUMAN; IMMUNOLOGY; LIVER TUMOR; NATURAL KILLER CELL;

ACTIVATION, METABOLIC; ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; FATTY LIVER; HEPATOCYTES; HUMANS; KILLER CELLS, NATURAL; LIVER NEOPLASMS; MICE; MICE, INBRED C57BL;

EID: 84907976095     PISSN: 15356108     EISSN: 18783686     Source Type: Journal    
DOI: 10.1016/j.ccell.2014.09.003     Document Type: Article

References (44)

1. Cancer Facts & Figures 2007, American Cancer Society, American Cancer Society. http://www.cancer.org/research/cancerfactsstatistics/cancerfactsfigures2007/index.
2. Anstee Q.M., Day C.P. The genetics of NAFLD. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:645-655.
3. Bhattacharjee J., Kumar J.M., Arindkar S., Das B., Pramod U., Juyal R.C., Majumdar S.S., Nagarajan P. Role of immunodeficient animal models in the development of fructose induced NAFLD. J.Nutr. Biochem. 2014, 25:219-226.
4. Caballero F., Fernández A., De Lacy A.M., Fernández-Checa J.C., Caballería J., García-Ruiz C. Enhanced free cholesterol, SREBP-2 and StAR expression in human NASH. J.Hepatol. 2009, 50:789-796.
5. Caballero T., Gila A., Sánchez-Salgado G., Muñoz de Rueda P., León J., Delgado S., Muñoz J.A., Caba-Molina M., Carazo A., Ruiz-Extremera A., Salmerón J. Histological and immunohistochemical assessment of liver biopsies in morbidly obese patients. Histol. Histopathol. 2012, 27:459-466.
6. Cairo S., Armengol C., De Reyniès A., Wei Y., Thomas E., Renard C.A., Goga A., Balakrishnan A., Semeraro M., Gresh L., et al. Hepatic stem-like phenotype and interplay of Wnt/beta-catenin and Myc signaling in aggressive childhood liver cancer. Cancer Cell 2008, 14:471-484.
7. Calle E.E., Kaaks R. Overweight, obesity and cancer: epidemiological evidence and proposed mechanisms. Nat. Rev. Cancer 2004, 4:579-591.
8. Cope K., Risby T., Diehl A.M. Increased gastrointestinal ethanol production in obese mice: implications for fatty liver disease pathogenesis. Gastroenterology 2000, 119:1340-1347.
9. Corbin K.D., Zeisel S.H. Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr. Opin. Gastroenterol. 2012, 28:159-165.
10. De Vito R., Alisi A., Masotti A., Ceccarelli S., Panera N., Citti A., Salata M., Valenti L., Feldstein A.E., Nobili V. Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. Int. J. Mol. Med. 2012, 30:49-56.
11. El-Serag H.B. Hepatocellular carcinoma. N.Engl. J. Med. 2011, 365:1118-1127.
12. Godfrey D.I., Pellicci D.G., Patel O., Kjer-Nielsen L., McCluskey J., Rossjohn J. Antigen recognition by CD1d-restricted NKT Tcell receptors. Semin. Immunol. 2010, 22:61-67.
13. Guerrerio A.L., Colvin R.M., Schwartz A.K., Molleston J.P., Murray K.F., Diehl A., Mohan P., Schwimmer J.B., Lavine J.E., Torbenson M.S., Scheimann A.O. Choline intake in a large cohort of patients with nonalcoholic fatty liver disease. Am. J. Clin. Nutr. 2012, 95:892-900.
14. Haybaeck J., Zeller N., Wolf M.J., Weber A., Wagner U., Kurrer M.O., Bremer J., Iezzi G., Graf R., Clavien P.A., et al. A lymphotoxin-driven pathway to hepatocellular carcinoma. Cancer Cell 2009, 16:295-308.
15. Hebbard L., George J. Animal models of nonalcoholic fatty liver disease. Nat. Rev. Gastroenterol. Hepatol. 2011, 8:35-44.
16. Henao-Mejia J., Elinav E., Jin C., Hao L., Mehal W.Z., Strowig T., Thaiss C.A., Kau A.L., Eisenbarth S.C., Jurczak M.J., et al. Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity. Nature 2012, 482:179-185.
17. Jemal A., Bray F., Center M.M., Ferlay J., Ward E., Forman D. Global cancer statistics. CA Cancer J. Clin. 2011, 61:69-90.
18. Kuziel W.A., Morgan S.J., Dawson T.C., Griffin S., Smithies O., Ley K., Maeda N. Severe reduction in leukocyte adhesion and monocyte extravasation in mice deficient in CC chemokine receptor 2. Proc. Natl. Acad. Sci. U S A 1997, 94:12053-12058.
19. Lo J.C., Wang Y., Tumanov A.V., Bamji M., Yao Z., Reardon C.A., Getz G.S., Fu Y.X. Lymphotoxin beta receptor-dependent control of lipid homeostasis. Science 2007, 316:285-288.
20. Lynch L., Nowak M., Varghese B., Clark J., Hogan A.E., Toxavidis V., Balk S.P., O'Shea D., O'Farrelly C., Exley M.A. Adipose tissue invariant NKT cells protect against diet-induced obesity and metabolic disorder through regulatory cytokine production. Immunity 2012, 37:574-587.
21. Maeda S., Kamata H., Luo J.L., Leffert H., Karin M. IKKbeta couples hepatocyte death to cytokine-driven compensatory proliferation that promotes chemical hepatocarcinogenesis. Cell 2005, 121:977-990.
22. Martin-Murphy B.V., You Q., Wang H., De La Houssaye B.A., Reilly T.P., Friedman J.E., Ju C. Mice lacking natural killer Tcells are more susceptible to metabolic alterations following high fat diet feeding. PLoS ONE 2014, 9:e80949.
23. Matsumoto M., Hada N., Sakamaki Y., Uno A., Shiga T., Tanaka C., Ito T., Katsume A., Sudoh M. An improved mouse model that rapidly develops fibrosis in non-alcoholic steatohepatitis. Int. J. Exp. Pathol. 2013, 94:93-103.
24. Michelotti G.A., Machado M.V., Diehl A.M. NAFLD, NASH and liver cancer. Nat. Rev. Gastroenterol. Hepatol. 2013, 10:656-665.
25. Miura K., Yang L., van Rooijen N., Ohnishi H., Seki E. Hepatic recruitment of macrophages promotes nonalcoholic steatohepatitis through CCR2. Am. J. Physiol. Gastrointest. Liver Physiol. 2012, 302:G1310-G1321.
26. Moeini A., Cornellà H., Villanueva A. Emerging signaling pathways in hepatocellular carcinoma. Liver Cancer 2012, 1:83-93.
27. Nakagawa H., Umemura A., Taniguchi K., Font-Burgada J., Dhar D., Ogata H., Zhong Z., Valasek M.A., Seki E., Hidalgo J., et al. ER stress cooperates with hypernutrition to trigger TNF-dependent spontaneous HCC development. Cancer Cell 2014, 26:331-343.
28. Park E.J., Lee J.H., Yu G.Y., He G., Ali S.R., Holzer R.G., Osterreicher C.H., Takahashi H., Karin M. Dietary and genetic obesity promote liver inflammation and tumorigenesis by enhancing IL-6 and TNF expression. Cell 2010, 140:197-208.
29. Petrasek J., Csak T., Ganz M., Szabo G. Differences in innate immune signaling between alcoholic and non-alcoholic steatohepatitis. J.Gastroenterol. Hepatol. 2013, 28(Suppl 1):93-98.
30. Pikarsky E., Porat R.M., Stein I., Abramovitch R., Amit S., Kasem S., Gutkovich-Pyest E., Urieli-Shoval S., Galun E., Ben-Neriah Y. NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature 2004, 431:461-466.
31. Pirola C.J., Gianotti T.F., Burgueño A.L., Rey-Funes M., Loidl C.F., Mallardi P., Martino J.S., Castaño G.O., Sookoian S. Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Gut 2013, 62:1356-1363.
32. Rubbia-Brandt L., Quadri R., Abid K., Giostra E., Malé P.J., Mentha G., Spahr L., Zarski J.P., Borisch B., Hadengue A., Negro F. Hepatocyte steatosis is a cytopathic effect of hepatitis C virus genotype 3. J.Hepatol. 2000, 33:106-115.
33. Satoh M., Andoh Y., Clingan C.S., Ogura H., Fujii S., Eshima K., Nakayama T., Taniguchi M., Hirata N., Ishimori N., et al. Type II NKT cells stimulate diet-induced obesity by mediating adipose tissue inflammation, steatohepatitis and insulin resistance. PLoS ONE 2012, 7:e30568.
34. Scheu S., Alferink J., Pötzel T., Barchet W., Kalinke U., Pfeffer K. Targeted disruption of LIGHT causes defects in costimulatory Tcell activation and reveals cooperation with lymphotoxin beta in mesenteric lymph node genesis. J.Exp. Med. 2002, 195:1613-1624.
35. Schlaeger C., Longerich T., Schiller C., Bewerunge P., Mehrabi A., Toedt G., Kleeff J., Ehemann V., Eils R., Lichter P., et al. Etiology-dependent molecular mechanisms in human hepatocarcinogenesis. Hepatology 2008, 47:511-520.
36. Stewart B.W., Wild C.P. World Cancer Report 2014 2014, WHO Press, Geneva, Switzerland.
37. Vucur M., Roderburg C., Bettermann K., Tacke F., Heikenwalder M., Trautwein C., Luedde T. Mouse models of hepatocarcinogenesis: what can we learn for the prevention of human hepatocellular carcinoma?. Oncotarget 2010, 1:373-378.
38. Wang Y., Koroleva E.P., Kruglov A.A., Kuprash D.V., Nedospasov S.A., Fu Y.X., Tumanov A.V. Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection. Immunity 2010, 32:403-413.
39. White D.L., Kanwal F., El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin. Gastroenterol. Hepatol. 2012, 10:1342-1359.e2.
40. Wunderlich F.T., Luedde T., Singer S., Schmidt-Supprian M., Baumgartl J., Schirmacher P., Pasparakis M., Brüning J.C. Hepatic NF-kappa B essential modulator deficiency prevents obesity-induced insulin resistance but synergizes with high-fat feeding in tumorigenesis. Proc. Natl. Acad. Sci. U S A 2008, 105:1297-1302.
41. Yoshimoto S., Loo T.M., Atarashi K., Kanda H., Sato S., Oyadomari S., Iwakura Y., Oshima K., Morita H., Hattori M., et al. Obesity-induced gut microbial metabolite promotes liver cancer through senescence secretome. Nature 2013, 499:97-101.
42. Zeisel S.H., Caudill M.A. Choline. Adv. Nutr. 2010, 1:46-48.
43. Zeisel S.H., da Costa K.A. Choline: an essential nutrient for public health. Nutr. Rev. 2009, 67:615-623.
44. Zender L., Villanueva A., Tovar V., Sia D., Chiang D.Y., Llovet J.M. Cancer gene discovery in hepatocellular carcinoma. J.Hepatol. 2010, 52:921-929.